Of course it's a failure. Some people are clearly in denial. To put it into perspective, if SAVA or BIVI or any other competing drug company reported this same data and issued the same PR, this message board would be erupting with joy and celebrating its failure. Another one bites the dust. Those who dare to speak up and say, "Not so fast, it still has a shot because it was clearly placebo effect" would be ridiculed and mocked by the WGT crowd.
And yet when it's Anavex that reports this data, the evangelists immediately rush to do damage control. For the record, I also think that despite the warts there's still a decent chance of approval for Rett syndrome if -- and only if -- the Rett parents get behind this the same way families did with Sarepta's drug candidate for Duchenne.
It's clear that Blarcamesine is not the super drug we all hoped that it would be. It does seem to have some potential as a placeholder. Perhaps A371 will prove to be a better drug candidate. If Blarcamesine was truly a game changer, one would think it would be able to overcome most any placebo groups no matter how strong the placebo effect may be.
I'm not going anywhere. I still view this investment as a lotto ticket. It's just not going to be a ticket that hits all 6 numbers which was the hope heading into the New Year.
News 
Market Data 
Discover 
